Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 11, Pages 1385-1400
Publisher
Informa Healthcare
Online
2013-09-12
DOI
10.1517/13543784.2013.824422
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Automated telephone reminders: Potential to improve adherence to adjuvant hormonal therapy among patients with breast cancer.
- (2017) Virginia P. Quinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.
- (2017) John C. Araujo et al. JOURNAL OF CLINICAL ONCOLOGY
- Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).
- (2017) Ian Tannock et al. JOURNAL OF CLINICAL ONCOLOGY
- Interaction among Cells of Bone, Immune System, and Solid Tumors Leads to Bone Metastases
- (2013) Ilaria Roato Clinical & Developmental Immunology
- Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor
- (2013) Aaron Rosenberg et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2013) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
- (2013) Nima Sharifi MOLECULAR ENDOCRINOLOGY
- The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward
- (2013) M. W. Kieran et al. Cold Spring Harbor Perspectives in Medicine
- Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
- (2013) Harrison et al. Cancer Management and Research
- Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
- (2013) John Araujo et al. Cancer Management and Research
- Systematic review/Meta-analysis Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
- (2012) Paweł Kawalec et al. Archives of Medical Science
- Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
- (2012) Jatinder Goyal et al. CANCER LETTERS
- Prostate cancer vaccines in clinical trials
- (2012) David M Lubaroff Expert Review of Vaccines
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
- (2012) D. Yee JNCI-Journal of the National Cancer Institute
- Wnt signaling pathways in urological cancers: past decades and still growing
- (2012) Shahana Majid et al. Molecular Cancer
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spontaneous Cancer-Stromal Cell Fusion as a Mechanism of Prostate Cancer Androgen-Independent Progression
- (2012) Ruoxiang Wang et al. PLoS One
- Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors
- (2012) Allan Lipton et al. Expert Review of Clinical Pharmacology
- The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development
- (2012) Paul G Corn Cancer Management and Research
- New drugs for prostate cancer
- (2011) Constantine Alifrangis et al. BJU INTERNATIONAL
- Dasatinib combined with docetaxel for castration-resistant prostate cancer
- (2011) John C. Araujo et al. CANCER
- Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib
- (2011) Paul Mathew et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular Alterations during Progression of Prostate Cancer to Androgen Independence
- (2011) P. Saraon et al. CLINICAL CHEMISTRY
- Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow
- (2011) Yusuke Shiozawa et al. JOURNAL OF CLINICAL INVESTIGATION
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
- (2011) A. J. Armstrong et al. MOLECULAR CANCER RESEARCH
- Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
- (2011) Kristin R. Lamont et al. MOLECULAR ENDOCRINOLOGY
- Targeting the endothelin axis in prostate carcinoma
- (2011) Álvaro Pinto et al. TUMOR BIOLOGY
- A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
- (2011) Young E. Whang et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases
- (2010) Carsten Nieder et al. BMC CANCER
- Epithelial plasticity, cancer stem cells and bone metastasis formation
- (2010) Gabri van der Pluijm BONE
- Targeted therapeutic approaches for hormone-refractory prostate cancer
- (2010) Flora Stavridi et al. CANCER TREATMENT REVIEWS
- Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
- (2010) T. B. Dorff et al. CLINICAL CANCER RESEARCH
- A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations
- (2010) E. Efstathiou et al. CLINICAL CANCER RESEARCH
- Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer
- (2010) M. Koutsilieris et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Epithelial-to-Mesenchymal Transitions and Circulating Tumor Cells
- (2010) Arnaud Bonnomet et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Examining the Metastatic Niche: Targeting the Microenvironment
- (2010) Theresa Guise SEMINARS IN ONCOLOGY
- An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer
- (2009) Carmel Pezaro et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Epithelial-mesenchymal transition in cancer development and its clinical significance
- (2009) Masaaki Iwatsuki et al. CANCER SCIENCE
- The Role of the Calcium-Sensing Receptor in the Development and Progression of Cancer
- (2009) Zuzana Saidak et al. ENDOCRINE REVIEWS
- Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology
- (2009) Pavlos Msaouel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression
- (2009) Elisabeth Jones et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Regulation of cell signalling by uPAR
- (2009) Harvey W. Smith et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1-associated osteoblastic changes
- (2009) Kouji Izumi et al. PROSTATE
- Mechanisms of bone metastasis in prostate cancer: clinical implications
- (2008) Pavlos Msaouel et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Wnt Signaling and Prostate Cancer
- (2008) Daniel Robinson et al. CURRENT DRUG TARGETS
- Implications of insulin-like growth factor-I for prostate cancer therapies
- (2008) Satoko Kojima et al. INTERNATIONAL JOURNAL OF UROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started